

Reference Number: FOI202122439
From: Commercial
Date: 19 January 2022
Subject: Medications prescribed for Psoriasis and Dermatology

Q1 How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Name of Drug

- a) Adalimumab - Humira
- b) Adalimumab Biosimilar
- c) Apremilast
- d) Bimekizumab
- e) Brodalumab
- f) Certolizumab
- g) Dimethyl fumarate
- h) Etanercept - Enbrel
- i) Etanercept Biosimilar
- j) Guselkumab
- k) Infliximab - Remicade
- l) Infliximab Biosimilar
- m) Ixekizumab
- n) Risankizumab
- o) Secukinumab
- p) Tildrakizumab
- q) Ustekinumab

- A1
- a) 1
 - b) 6
 - c) 0
 - d) 0
 - e) 0
 - f) 0
 - g) 0
 - h) 0
 - i) 1
 - j) 0
 - k) 0
 - l) 0
 - m) 0
 - n) 0
 - o) 0
 - p) 0
 - q) 2

Q2 How many patients have been treated for Psoriasis ONLY in the last three months with

the following:

- a) Ciclosporin
- b) Methotrexate - any form and strength
- c) Methotrexate injections 15mg and above

A2

- a) 0
- b) 1
- c) 0